US flu dose distributions and early-season vaccination rates are up 10% and 6% respectively for the 2018-19 season. Macquarie expects a positive mix shift which will support the near-term outlook for Seqirus.
Moreover, a pipeline of late-stage products are in development and there are additional growth avenues over the medium to longer term. Outperform rating maintained. Target is $230.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is $230.00.Current Price is $190.95. Difference: $39.05 – (brackets indicate current price is over target). If CSL meets the Macquarie target it will return approximately 17% (excluding dividends, fees and charges – negative figures indicate an expected loss).
